Fundies.
English

Segment disclosures

Company overview

Certara, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

5 dimension combinations 29 retained observations 12 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Reportable Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cert:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3093271000 USD20260804Open filing evidence
2026-01-01 – 2026-06-30187363000 USD20260804Open filing evidence
2026-01-01 – 2026-03-31106915000 USD20260511Open filing evidence
2025-01-01 – 2025-12-31418838000 USD20260226Open filing evidence
2025-07-01 – 2025-09-30104616000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30315190000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3092356000 RestatedUSD20260804Open filing evidence
2025-01-01 – 2025-06-30184455000 RestatedUSD20260804Open filing evidence
2025-01-01 – 2025-03-31106004000 USD20260511Open filing evidence
2024-01-01 – 2024-12-31385148000 USD20260226Open filing evidence
2024-07-01 – 2024-09-3094820000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30284787000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3093313000 USD20250806Open filing evidence
2024-01-01 – 2024-06-30189967000 USD20250806Open filing evidence
2024-01-01 – 2024-03-3196654000 USD20250505Open filing evidence
2023-01-01 – 2023-12-31354337000 USD20260226Open filing evidence
2022-01-01 – 2022-12-31335644000 USD20250226Open filing evidence

Americas · Bio Simulation Technology Segment

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=srt:AmericasMember;us-gaap:StatementBusinessSegmentsAxis=cert:BioSimulationTechnologySegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-12-31281493000 USD20250226Open filing evidence
2023-01-01 – 2023-12-31265063000 USD20250226Open filing evidence
2022-01-01 – 2022-12-31252921000 USD20250226Open filing evidence

Asia Pacific · Bio Simulation Technology Segment

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=cert:BioSimulationTechnologySegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-12-3127088000 USD20250226Open filing evidence
2023-01-01 – 2023-12-3125707000 USD20250226Open filing evidence
2022-01-01 – 2022-12-3125721000 USD20250226Open filing evidence

EMEA · Bio Simulation Technology Segment

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=cert:BioSimulationTechnologySegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-12-3176567000 USD20250226Open filing evidence
2023-01-01 – 2023-12-3163567000 USD20250226Open filing evidence
2022-01-01 – 2022-12-3157002000 USD20250226Open filing evidence

Bio Simulation Technology Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cert:BioSimulationTechnologySegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-12-31385148000 USD20250226Open filing evidence
2023-01-01 – 2023-12-31354337000 USD20250226Open filing evidence
2022-01-01 – 2022-12-31335644000 USD20250226Open filing evidence